Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab plus pemetrexed and carboplatin for first-line advanced nonsquamous NSCLC with brain metastases
ChiCTR2400083739Phase 2Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Apr 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab, pemetrexed and carboplatin in non-small cell lung cancer (NSCLC), sponsored by Jiangsu Provincial People's Hospital. Primary endpoints: intracranial objective response rate and intracranial disease control rate. Started Apr 2024; status: recruiting.
02
Drugs
adebrelimabpemetrexedcarboplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400083739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400083739.